Drug Profile


Alternative Names: AcSDKP; BIM 32001; BN 52040; Seraspenide

Latest Information Update: 23 Aug 2002

Price : $50

At a glance

  • Originator Ipsen
  • Class Oligopeptides; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chemoprotection; Haematological disorders; Transplant rejection

Most Recent Events

  • 11 Jun 1997 Preclinical development for Haematological disorders in France (Unknown route)
  • 24 Jan 1995 Phase-II clinical trials for Transplant rejection in Germany (Unknown route)
  • 24 Jan 1995 Phase-II clinical trials for Transplant rejection in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top